US2010297033A1PendingUtilityA1

Megaribavirin alone or combination of other antiviral, antioxidant and a perflubron emulsion for treatment of viral disease

66
Individually held — no corporate assignee on recordPriority: May 21, 2009Filed: May 21, 2009Published: Nov 25, 2010
Est. expiryMay 21, 2029(~2.8 yrs left)· nominal 20-yr term from priority
Inventors:Matthew T. Mcleay
A61K 38/446A61K 9/008A61K 31/198A61K 45/06A61K 31/215A61K 31/351C12Y 115/01001A61K 31/7056
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is a novel method using a MegaRibavirin aerosol or a MegaRibavirin combination of therapeutics for the treatment of viral disease particularly the pandemic influenza strains “swine” 2009 H1N1 and H5N1. This invention utilizes Ribavirin in an aerosol Mega Dose (61-161 mg/ml) alone or combined with or without other antivirals, a perfluorocarbon emulsion and anti-inflammatory/anti-oxidants. Where applicable, the perfluorocarbon emulsion may dissolve these agents enabling a depot effect and possible protracted delivery. In addition perfluorocarbon emulsions have the possible added benefit of oxygen carrying capacity and alveolar nitric oxide sequestration, which may reduce peroxynitrite formation and decrease Influenza severity.

Claims

exact text as granted — not AI-modified
1 . A method of treatment for a patient with influenza e.g. swine 2009 H1N1 and H5N1 or other viral disease 
     
     
         2 . The method of  claim 1  wherein Ribavirin in a “MegaRibavirin” concentration (greater than 61 and less than 161 mg/ml) is utilized as an aerosol. 
     
     
         3 . The method of  claim 1  wherein said MegaRibavirin is administered in a form selected from the group consisting of liquids, aerosols, mists, air-borne suspensions, vapors and combinations thereof. 
     
     
         4 . The method of  claim 1  wherein said MegaRibavirin is administered comprising a delivery mode consisting of intratracheal instillation or aerosol resulting in both local pulmonary but also systemic administration. 
     
     
         5 . The method of  claim 1  wherein said MegaRibavirin is combined with other antiviral agents such as but not limited to zanamivir or oseltamivir. 
     
     
         6 . The method of  claim 5  wherein said MegaRibavirin and antiviral combination is in a form selected from the group consisting of liquids, aerosols, mists, air-borne suspensions, vapors and combinations thereof. 
     
     
         7 . The method of  claim 5  wherein said MegaRibavirin is administered comprising a delivery mode consisting of intratracheal instillation or aerosol resulting in both local pulmonary but also systemic administration. 
     
     
         8 . The method of  claim 2  wherein said MegaRibavirin is combined with a perfluorocarbon emulsion such as but not limited to a perflubron emulsion. 
     
     
         9 . The method of  claim 8  in a form selected from the group consisting of liquids, aerosols, mists, air-borne suspensions, vapors and combinations thereof. 
     
     
         10 . The method of  claim 8  wherein said MegaRibavirin is administered with a perfluorocarbon emulsion comprising a delivery mode consisting of intratracheal instillation or aerosol resulting in both local pulmonary but also systemic administration. 
     
     
         11 . The method of  claim 5  wherein said MegaRibavirin and antiviral is combined with a perfluorocarbon emulsion such as but not limited to a perflubron emulsion. 
     
     
         12 . The method of  claim 11  in a form selected from the group consisting of liquids, aerosols, mists, air-borne suspensions, vapors and combinations thereof. 
     
     
         13 . The method of  claim 11  is administered with a perfluorocarbon emulsion comprising a delivery mode consisting of intratracheal instillation or aerosol resulting in both local pulmonary but also systemic administration. 
     
     
         14 . The method of  claim 2  wherein said MegaRibavirin is combined with an antioxidant or anti inflammatory such as but not limited to N acetylcysteine or superoxide dismutase. 
     
     
         15 . The method of  claim 14  in a form selected from the group consisting of liquids, aerosols, mists, air-borne suspensions, vapors and combinations thereof. 
     
     
         16 . The method of  claim 14  wherein said MegaRibavirin is administered with a perfluorocarbon emulsion comprising a delivery mode consisting of intratracheal instillation or aerosol resulting in both local pulmonary but also systemic administration. 
     
     
         17 . The method of  claim 5  wherein said MegaRibavirin and antiviral is combined with an antioxidant or anti inflammatory such as but not limited to N acetylcysteine or superoxide dismutase. 
     
     
         18 . The method of  claim 17  in a form selected from the group consisting of liquids, aerosols, mists, air-borne suspensions, vapors and combinations thereof. 
     
     
         19 . The method of  claim 18  wherein the fluorocrit of the perfluoro compound in the blood stream is at least about 3%. 
     
     
         20 . The method of  claim 8  wherein said MegaRibavirin and an antiviral is administered with a perfluorocarbon emulsion combined with an antioxidant or anti inflammatory such as but not limited to N acetylcysteine or superoxide dismutase. 
     
     
         21 . The method of  claim 20  in a form selected from the group consisting of liquids, aerosols, mists, air-borne suspensions, vapors and combinations thereof. 
     
     
         22 . The method of  claim 20  wherein is administered comprising a delivery mode consisting of intratracheal instillation or aerosol resulting in both local pulmonary but also systemic administration. 
     
     
         23 . The method of claim further comprising the step of administering the breathing gas oxygen simultaneously with said fluorocarbon emulsion.

Join the waitlist — get patent alerts

Track US2010297033A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.